A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Study of Gantenerumab in Patients With Mild Alzheimer's Disease; Part II: Open-Label Extension For Participating Patients
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Gantenerumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms Marguerite RoAD
- Sponsors Chugai Pharmaceutical; Roche
- 10 Jun 2017 Biomarkers information updated
- 25 Jan 2017 Open label extension part II has been added in the study hence protocol amended.
- 03 Oct 2016 Status changed from recruiting to active, no longer recruiting.